All funds

DNB Bioteknologi A

Equity fund

1 year

Globe

USA

Largest region

High

Risk

Annual costs

Morningstar

 

Partial 

Sustainability

Development

Last 5 years
( ann.)

Details

  • Fondet er et aksjefond som investerer hovedsakelig i aksjer (verdipapirer som representerer en eierandel i et selskap) notert på børser og regulerte markeder over hele verden, innenfor sektorene bioteknologi, diagnostikk, farmasi, produksjon av farmasøytiske produkter, biologiske legemidler herunder genterapi, og annen helserelatert virksomhet. Det vil også være anledning til å investere innenfor selskaper som har deler av sitt virke tilknyttet helse.
    Read more

Investment horizon

  • DNB Bioteknologi A is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • NAV/Price
  • Margin rate
  • Start date
  • ISIN
    NO0010877707

Risk

  • High (5 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Annual cost

  • Ongoing costs
    Includes management fees of 0,85 %
  • Platform fee
  • Kickback fee
  • Annual running costs

Other costs

  • Performance-based fee
  • Transaction costs

  • Costs for any currency exchanges are not included.

Allocation

  • Stocks 95%
    Interest 5%

Portfolio

Shows the fund's largest investments.

  • argenx SE
    7.1%
  • BioMarin Pharmaceutical Inc
    5.4%
  • Insmed Inc
    4.4%
  • Neurocrine Biosciences Inc
    3.6%
  • Axsome Therapeutics Inc
    3.6%
DNB Bioteknologi A - Buy mutual fund - DNB